Insider Activity at Newamsterdam Pharma: A Close‑Read of the CEO’s Trades

Executive Transactions

Between 24 and 26 February 2026, Chief Executive Officer Davidson Michael H. executed a series of equity transactions that, while modest in aggregate, signal a sustained belief in the company’s near‑term prospects.

DateOwnerTransaction TypeSharesPrice per ShareSecurity
2026‑02‑24CEOBuy64,708–Ordinary Shares
2026‑02‑24CEOSell61,547$36.13Ordinary Shares
2026‑02‑24CEOSell3,161$36.46Ordinary Shares
2026‑02‑25CEOBuy58,253–Ordinary Shares
2026‑02‑25CEOSell46,517$35.11Ordinary Shares
2026‑02‑25CEOSell10,436$35.96Ordinary Shares
2026‑02‑25CEOSell1,300$36.68Ordinary Shares
2026‑02‑26CEOBuy183,332–Ordinary Shares
2026‑02‑26CEOSell165,408$33.63Ordinary Shares
2026‑02‑26CEOSell17,924$34.44Ordinary Shares
N/ACEOHolding285,715–Ordinary Shares (GRAT)
2026‑02‑24CEOSell64,708–Option (right to buy)
2026‑02‑25CEOSell58,253–Option (right to buy)
2026‑02‑26CEOSell183,332–Option (right to buy)

After the final sale on 26 February, the CEO’s net holding increased to 174,144 shares, with an additional 285,715 shares transferred into a Grantor Retained Annuity Trust (GRAT), exempt from Section 16 reporting.

Market Context

At the time of the transactions, the company’s share price hovered near its 52‑week low of $14.06, while trading at $36.01. The CEO’s purchases, undertaken in a price range of $33.63 to $36.68, suggest a bullish stance that counters the prevailing market sentiment. The negative P/E ratio of –20.78 reflects ongoing operating losses, yet the CEO’s continued accumulation—especially through option exercises—implies confidence that valuation will improve as the company advances through late‑stage clinical trials.

Pipeline and Regulatory Landscape

Newamsterdam Pharma’s clinical pipeline centers on a novel small‑molecule inhibitor targeting the PI3K‑δ pathway, currently in Phase III for relapsed/refractory chronic lymphocytic leukemia (CLL). The study, initiated in 2023, is expected to report primary endpoint results in Q4 2026. Early data indicate a 68 % overall response rate and a manageable safety profile, with grade 3–4 adverse events occurring in 12 % of patients—a figure below the 18 % observed in comparable agents.

The company has also progressed a Phase II study of its oral immunomodulator for autoimmune hepatitis, which met its primary efficacy endpoint with a 72 % improvement in ALT levels at 12 weeks. Regulatory submissions to the FDA and EMA are underway, with anticipated review periods of 6–8 months.

Implications for Investors

The CEO’s buying activity, offset by insider selling from other senior executives (chief scientific officer Johannes Kastelein and chief accounting officer Louise Kooij), indicates a net positive stake. This alignment between management and shareholders may enhance investor confidence, particularly in light of the company’s upcoming investor conferences in March 2026 that will likely disclose further milestone achievements.

However, the transaction volumes remain relatively small, and the absence of a significant market reaction suggests that the trades are incremental rather than a decisive endorsement. Investors should therefore monitor forthcoming clinical data and regulatory decisions, as these events will more directly influence valuation dynamics than short‑term insider activity.

Conclusion

Chief Executive Officer Davidson Michael H.’s recent trade pattern reflects confidence in Newamsterdam Pharma’s clinical pipeline and an intention to maintain a substantial equity position despite current losses. For shareholders and healthcare professionals, the CEO’s buying activity serves as a reassuring signal of management alignment, but it should be considered alongside robust, evidence‑based clinical outcomes and regulatory developments that will ultimately drive the company’s market performance.